Clinical trial
Ablation of Intestinal Metaplasia Containing Dysplasia
NCT00282672 · Medtronic - MITG, Industry · Completed
Key facts
| NCT number | NCT00282672 |
|---|---|
| Title | Ablation of Intestinal Metaplasia Containing Dysplasia |
| Official title | Ablation of Intestinal Metaplasia Containing Dysplasia (AIM Dysplasia Trial) A Multi-center, Randomized, Sham-Controlled Trial: Protocol Amendment to Extend Follow-up to 5 Years |
| Lead sponsor | Medtronic - MITG, Industry |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Barrett Esophagus |
| Intervention type | Device |
| Interventions | Ablation System plus anti-secretory medication, Sham procedure plus anti-secretory medication |
| Enrollment | 127 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2014 |
| Completion | Aug 1, 2014 |
| First posted | Jan 27, 2006 |
| Last update posted | Nov 6, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: